XML 47 R37.htm IDEA: XBRL DOCUMENT v3.22.2
Commitments and contingencies - Pfizer Option and License Agreement - (Details)
$ in Thousands
6 Months Ended
Oct. 01, 2021
USD ($)
item
Jun. 30, 2022
USD ($)
Mar. 04, 2022
USD ($)
Dec. 31, 2021
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Revenue recognized | $   $ 1,214    
Deferred revenue | $   10,881   $ 12,096
Pfizer | Option and license agreement        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Number of transgenes 2      
Number of options 1      
Number of options exercised 0      
Number of performance obligations 2      
Number of material rights 2      
Upfront payment | $ $ 30,000      
Number of license options 1      
Allocation of transaction price | $     $ 15,000  
Aggregate milestone payments, if exercise rights | $ $ 10,000      
Deferred revenue | $   $ 30,000    
Number of days written notice required by reporting entity to terminate agreement 90 days      
Pfizer | Development, regulatory and commercialization milestone | Option and license agreement        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Aggregate maximum milestone payments to be received from collaborative partner | $ $ 115,000      
Pfizer | Sales milestone | Option and license agreement        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Aggregate maximum milestone payments to be received from collaborative partner | $ $ 175,000      
Minimum | Pfizer | Option and license agreement        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Number of countries received regulatory approval 1      
Number of major market countries received regulatory approval 1      
Maximum | Pfizer | Option and license agreement        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Number of options exercised 1